Every 10-Q that Centessa Pharmaceuticals Plc (CNTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CNTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTA filings page.
Centessa Pharmaceuticals reported a larger net loss while agreeing to be acquired by Eli Lilly. For the quarter ended March 31, 2026, net loss widened to $79.2 million from $26.1 million, driven mainly by higher research and development spending and the absence of prior-year licensing revenue.
Research and development expenses rose to $59.9 million from $33.4 million, and general and administrative costs increased to $19.9 million. The company reported no license and other revenue versus $15.0 million a year earlier. Cash, cash equivalents and investments totaled $533.7 million, which management expects to fund operations into mid-2028.
On March 31, 2026, Centessa agreed to be acquired by Eli Lilly via a UK court-sanctioned Scheme of Arrangement for $38.00 in cash per share plus up to $9.00 per share in contingent value rights tied to future regulatory milestones for its orexin programs. The deal is expected to close in the third quarter of 2026, subject to shareholder, court and regulatory approvals.
Centessa Pharmaceuticals (CNTA) reported Q3 2025 results. The company recorded a net loss of $54.9M for the quarter and $131.4M for the nine months. As of September 30, 2025, cash, cash equivalents and investments totaled $349.0M, and management stated this is expected to fund operations into mid-2027.
Operating expenses reflect continued pipeline investment: Q3 research and development was $41.6M and general and administrative was $12.2M. Year-to-date license and other revenue was $15.0M, primarily from an upfront payment under the Genmab LockBody license. Long-term debt stood at $110.0M principal (maturing in 2029). The company raised $6.1M in net proceeds via its ATM during the nine months. Shares outstanding were 134,447,836 ordinary shares as of October 31, 2025.
The SerpinPC program discontinuation charges recognized in 2024 were largely settled by Q3 2025, with the related contract termination liability effectively extinguished.
Centessa Pharmaceuticals plc (CNTA) reported interim results through June 30, 2025 showing continued clinical progress and a material licensing transaction. For the six months ended June 30, 2025 the company recorded a net loss of $76.5 million versus $81.9 million in the prior year period, with research and development expense of $76.2 million driven primarily by the OX2R agonist programs. Centessa recognized a $15.0 million upfront payment from a LockBody license to Genmab and constrained additional milestone consideration pending achievement. As of June 30, 2025 the company held $404.1 million of cash, cash equivalents and investments and expects those resources to fund operations into mid-2027. The balance sheet shows $109.5 million of long-term debt and an accumulated deficit of $1.07 billion. Operational updates include ORX750 in an ongoing Phase 2a study, IND clearance and Phase 1 initiation for ORX142, and the prior-phase discontinuation of SerpinPC with related termination charges largely paid down.